Table 1. Baseline characteristics in cases and controls.
Baseline characteristics such as age at the time of recruitment, primary tumor type, prior lines of chemotherapy, performance status were balanced between cases and controls.
| Cases | Controls | ||
|---|---|---|---|
| Study subjects (single agent therapy) | 366 | 100 | |
| Age, Year Median (Range) | 56.7 (22-81) | 54.3 (17-88) | |
| Gender | Male | 179 | 53 |
| Female | 187 | 47 | |
| BMI, Kg/m2 Median (Range) | 25.9 (16.9-43) | 26.8 (18.3- 38) | |
| Tumor type (All cases, single agents and combinations) | Lung & Mesothelioma | 49 (13%) | 11 (11%) |
| Breast | 34 (9.3%) | 11 (11%) | |
| Colorectal | 95 (26%) | 16 (16%) | |
| Gynecological | 61 (16.6%) | 6 (6%) | |
| RCC | 18 (5%) | 3 (3%) | |
| Prostate | 22 (6.8%) | 10 (10%) | |
| Others | 87 (23.7%) | 43 (43%) | |
| No of prior lines of chemotherapy | 0-2 | 183 (50%) | 52 (52%) |
| 3-5 | 148 (40.5%) | 36 (36%) | |
| >6 | 20 (5.5%) | 4 (4%) | |
| Unknown | 15 (4%) | 8 (8%) | |
| Performance Status | 0 | 88 (24%) | 26 (26%) |
| 1 | 276 (75%) | 72 (72%) | |
| 2 | 2 (0.5%) | 2 (2%) | |
| RM Score * | 0 | 68 (18.5%) | 22 (22%) |
| 1 | 129 (35%) | 30 (30%) | |
| 2 | 106 (29%) | 32 (32%) | |
| 3 | 52 (14.5%) | 16 (16%) | |
| Unknown | 11 (3%) | - | |
| Time on trial (days) | 84 | 109 | |
*
RM score (reference): Albumin + No. metastatic sites + LDH